Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
Rhea-AI Summary
BioArctic (NASDAQ: B) reports that Leqembi global sales were JPY 20.7 billion in Q4 2025, generating a royalty to BioArctic of SEK 127 million. This royalty rose ~31% versus Q4 2024; at constant exchange rates the SEK increase would be ~50%, reflecting currency effects.
Eisai will publish its Q3 FY2025 results on February 9, 2026 and BioArctic will publish its FY2025 report on February 18, 2026 at 08:00 CET.
Positive
- Leqembi sales of JPY 20.7 billion in Q4 2025
- Royalty to BioArctic of SEK 127 million in Q4 2025
- Royalty increase ~31% YoY versus Q4 2024
- Currency-adjusted royalty growth of ~50% at constant exchange rates
Negative
- Strong SEK appreciation drove much of the reported royalty growth, complicating revenue comparability
News Market Reaction – B
On the day this news was published, B gained 2.71%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Several gold peers were also down (e.g., WPM -3.28%, FNV -3.03%, AEM -2.24%, KGC -2.16%), while AU rose 1.54%, indicating mixed but generally weak sector action alongside the stock’s -7.16% move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Pipeline strategy update | Positive | -0.4% | Broadened development focus of CS014 to PH-ILD after Phase I study. |
| Jan 21 | Corporate reorganization | Neutral | +0.3% | Creation of new U.S. and International operating divisions and leadership changes. |
| Jan 14 | Clinical publication | Positive | +0.5% | Peer-reviewed data on CS014 showing antithrombotic efficacy without added bleeding risk. |
| Jan 13 | Leadership appointments | Positive | +1.4% | New executive appointments to support growth and potential Octave spinoff. |
| Jan 07 | Earnings date notice | Neutral | -1.0% | Announcement of timing for full year and Q4 2025 results release and webcast. |
Recent news has often seen modest price moves, with at least one instance of negative reaction to seemingly positive clinical development.
Over the last month, the ticker has been linked to varied news items across different issuers. A Jan 7 earnings-date announcement for Barrick saw a modest -0.98% move. Other items, including clinical updates for CS014 and leadership changes at Hexagon US Federal, produced small price reactions between about -0.36% and +1.39%. Against this backdrop of generally contained responses, the current -7.16% move ahead of the royalty-focused Leqembi update stands out as comparatively larger.
Market Pulse Summary
This announcement highlighted Leqembi’s preliminary Q4 2025 sales of JPY 20.7 billion, generating a SEK 127 million royalty to BioArctic, about 31% higher than Q4 2024 and roughly 50% higher at constant FX. Investors may track upcoming dates such as Eisai’s Q3 FY2025 results on February 9, 2026 and BioArctic’s full-year 2025 report on February 18, 2026 to gauge how these royalties feed into broader financial performance and guidance.
Key Terms
eu market abuse regulation regulatory
AI-generated analysis. Not financial advice.
The strong appreciation of the Swedish krona during 2025 has had a significant impact on the growth of royalty received in the fourth quarter. With constant exchange rates, the increase in recorded royalty in SEK would have been approximately 50 percent.
Eisai's results for their third quarter FY2025 (Oct-Dec 2025) will be published on February 9, 2026.
BioArctic's report for the full year 2025 will be published on February 18, 2026, at 08:00 CET.
This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on February 6, 2026, at 12:00 CET.
For further information, please contact:
Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180
Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08
About Leqembi® (lecanemab)
Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).
Leqembi is approved in 53 countries and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 7 countries, including the
Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in
About the collaboration between BioArctic and Eisai
Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Sales of Leqembi® totaled |
View original content:https://www.prnewswire.com/news-releases/sales-of-leqembi-totaled-20-7-billion-yen-in-the-fourth-quarter-2025--302681249.html
SOURCE CISION AB
FAQ
How much did Leqembi sell worldwide in Q4 2025 and what royalty did BioArctic (B) receive?
Why does BioArctic (B) say royalty growth was larger at constant exchange rates for Q4 2025?
When will Eisai and BioArctic publish follow-up financial reports related to Q4 2025?
Does the Q4 2025 royalty to BioArctic (B) reflect actual business growth or currency effects?
How does the Q4 2025 royalty result affect BioArctic's disclosure schedule (B)?
